- US12617846utility2026Subcutaneous (SC) Administration of Anti-c5 Antibodies for Treatment of Complement-associated Conditions0 cites
- US12612451utility2026Method of Treating Neuromyelitis Optica Spectrum Disorder (NMOSD) Comprising Administering an Anti-c5 Antibody0 cites
- US12611447utility2026Methods for Treating Bone Mineralization Disorders0 cites
- US12590977utility2026Anti-ceruloplasmin Antibodies and Uses Thereof0 cites
- US12497445utility2025Monovalent Anti-properdin Antibodies and Antibody Fragments0 cites
- US12459992utility2025Methods for Treatment of Refractory Generalized Myasthenia Gravis0 cites
- US12433938utility2025Alkaline Phosphatase Polypeptides and Methods of Use Thereof0 cites
- US12428484utility2025Anti-alk2 Antibodies and Uses Thereof0 cites
- US12398387utility2025Compositions and Methods for Preparing Factor Xa and Derivatives0 cites
- US12350269utility2025Cerdulatinib for the Treatment of B-cell Malignancies0 cites
- US12312394utility2025Methods of Producing Anti-c5 Antibodies0 cites
- US12268733utility2025Methods of Treating Neurofibromatosis Type 1 and Related Conditions with Alkaline Phosphatase0 cites
- US12221473utility2025Polypeptides That Bind Complement Component C5 or Serum Albumin and Fusion Proteins Thereof0 cites
- US12195774utility2025Antidotes to Factor XA Inhibitors0 cites
- US12150942utility2024Cerdulatinib for Treating Myeloma0 cites
- US12139533utility2024Liquid Formulations of Anti-cd200 Antibodies0 cites
Page 1 of 3Next →